查看購物車
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1941553

多形性膠質母細胞瘤治療市場規模、佔有率和趨勢分析報告：按療法、最終用途、地區和細分市場預測（2026-2033 年）

Glioblastoma Multiforme Treatment Market Size, Share & Trends Analysis Report By Treatment (Surgery, Radiation Therapy, Chemotherapy), By End Use (Hospitals, Ambulatory Surgery Centers), By Region, And Segment Forecasts, 2026 - 2033
出版日期: | 出版商: Grand View Research | 英文 150 Pages | 商品交期: 2-10個工作天內

價格

多形性膠質母細胞瘤治療市場概況

2025年全球多形性膠質母細胞瘤治療市場規模估計為40.4億美元，預計2033年將達到78.7億美元。

預計從 2026 年到 2033 年，該行業將以 8.69% 的複合年成長率成長。多形性膠質母細胞瘤 (GBM) 的盛行率不斷上升及其帶來的重大臨床負擔是 GBM 治療行業的關鍵促進因素。

越來越多的依證強化了替Temozolomide（TMZ）作為膠質母細胞瘤（GBM）治療基石藥物的地位。近期真實世界研究和Meta分析表明，將TMZ療程延長至標準的六個療程之後，可能帶來額外的生存獲益，尤其是在具有良好分子特徵（例如MGMT啟動子甲基化水平低和Ki-67表達低）的患者中。發表於2023年7月《神經腫瘤學進展》（Neuro-Oncology Advances）的Meta分析，檢驗了來自16項非隨機研究和5項隨機對照試驗的2578例患者的數據。分析結果顯示，延長療程可使疾病進展風險降低28%，死亡風險降低29%，但這些獲益大多是在回顧性隊列研究中觀察到的。這些發現凸顯了進行更多隨機試驗以確定其作為輔助性治療長期應用價值的必要性。此外，鑑於替莫唑胺的耐受性和一致的臨床療效，目前正在進行評估聯合治療的臨床試驗。

成本效益和廣泛的可及性也是替莫唑胺（TMZ）在全球範圍內被廣泛應用的原因之一。學名藥的推出降低了治療成本，提高了患者的可及性，且不影響治療效果。其良好的安全性和確切的療效使其成為不同醫療體系中的首選治療方案。 2023年3月發表於《臨床腫瘤學雜誌》（Journal of Clinical Oncology）的一項IIa期研究評估了TMZ聯合SurVaxM疫苗作為輔助性治療治療新診斷膠質母細胞瘤患者的療效。結果顯示，患者的中位無惡化生存期為11.4個月，總存活期為25.9個月，且免疫反應強勁，嚴重的疫苗相關副作用，支持了聯合治療的潛力。即使新的治療方法不斷湧現，許多治療方法仍以TMZ為基礎，這再次鞏固了TMZ在膠質母細胞瘤標準治療中的關鍵地位。

腫瘤電場療法（TTF）在全球的普及速度持續加快，這得益於其應用範圍的擴大和有利的醫保政策。許多醫療系統已將TTF納入醫保報銷範圍，從而降低了合格患者的經濟負擔。截至2024年底，Novocure公司報告稱，全球已有超過4,000名患者正在積極使用Optune Gio TTF系統，其中美國、德國、法國和日本等地區的普及率較高。不斷成長的使用者群體反映出醫生對該治療方法的接受度不斷提高。良好的治療效果也推動了技術創新，人們正持續致力於技術升級和拓展至其他腫瘤類型。這些進展共同促成了TTF在進行性多形性膠質母細胞瘤治療發展過程中的重要地位。

五年存活數據顯示，不同治療方法的存活率有顯著差異：單純放射線治療（RT）的存活率為16.2%，而合併替Temozolomide（TMZ）治療的存活率高達83.8%。這顯示聯合治療具有顯著的臨床優勢，尤其體現在Temozolomide對改善多形性膠質母細胞瘤患者預後的貢獻。這些發現支持繼續將替Temozolomide作為多形性膠質母細胞瘤治療的基石，並強化了聯合通訊協定中對化療藥物的需求。此外，這些發現也為醫療服務提供者傾向於採用綜合治療方法提供了證據，從而促進了聯合治療在臨床實踐中的應用。

從市場觀點來看，存活率的提高將繼續推動聯合治療的投資，進而帶動對替莫唑胺（TMZ）等輔助性治療的需求。製藥公司有望利用這些進展，開發下一代治療方法，例如免疫療法和標靶治療，以補充和增強TMZ的療效。放射線治療合併TMZ的高存活率將影響治療指南，從而擴大保險覆蓋範圍，並提高醫院和癌症中心的採用率。這種轉變不僅將維持TMZ在膠質母細胞瘤（GBM）治療市場的主導地位，也將為新型輔助性治療創造機會。

目錄

第1章調查方法和範圍

第2章執行摘要

3. 多形性膠質母細胞瘤治療市場變數、趨勢和範圍

  • 市場譜系展望
  • 市場動態
  • 商業環境分析
    • 產業分析—波特五力分析
    • PESTLE分析
    • 管道分析
    • 專利到期分析
    • 定價分析

第4章 多形性膠質母細胞瘤治療市場：治療業務分析

  • 按療法分類的市場佔有率（2025 年和 2033 年）
  • 按治療方法分類的市場規模、預測和趨勢分析（2021-2033 年）
  • 外科手術
  • 放射線治療
  • 化療
  • 標靶治療（Bevacizumab）
  • 腫瘤電場治療（TTF）

5. 多形性膠質母細胞瘤治療市場：依最終用途分類的業務分析

  • 按最終用途分類的市場佔有率（2025 年和 2033 年）
  • 按最終用途分類的市場規模、預測和趨勢分析（2021年至2033年）
  • 醫院
  • 診所/門診中心
  • 門診手術中心
  • 其他

第6章 多形性膠質母細胞瘤治療市場：區域估算與趨勢分析

  • 區域市場佔有率分析（2025 年和 2033 年）
  • 區域市場概覽
  • 市場規模及預測趨勢分析（2021-2033）：
  • 北美洲
    • 美國
    • 加拿大
    • 墨西哥
  • 歐洲
    • 英國
    • 德國
    • 法國
    • 義大利
    • 西班牙
    • 丹麥
    • 瑞典
    • 挪威
  • 亞太地區
    • 日本
    • 中國
    • 印度
    • 澳洲
    • 韓國
    • 泰國
  • 拉丁美洲
    • 巴西
    • 阿根廷
  • 中東和非洲
    • 南非
    • 沙烏地阿拉伯
    • 阿拉伯聯合大公國
    • 科威特

第7章 競爭情勢

  • 參與公司概況
  • 企業市場分析
  • 公司分類
  • 策略規劃
  • 公司簡介/列表
    • Merck &Co., Inc.
    • Amgen, Inc.
    • F. Hoffmann-La Roche Ltd.
    • Pfizer Inc.
    • Teva Pharmaceutical Industries Ltd.
    • Sun Pharmaceutical Industries Ltd.
    • Arbor Pharmaceuticals, LLC
    • Amneal Pharmaceuticals
    • Karyopharm Therapeutics, Inc.
    • Sumitomo Dainippon Pharma Oncology, Inc.（Boston Biomedical, Inc.）
Product Code: GVR-4-68039-527-3

Glioblastoma Multiforme Treatment Market Summary

The global glioblastoma multiforme treatment market size was estimated at USD 4.04 billion in 2025 and is projected to reach USD 7.87 billion by 2033, growing at a CAGR of 8.69% from 2026 to 2033. The rising prevalence of Glioblastoma Multiforme (GBM) and its significant clinical burden are critical drivers in the GBM treatment industry.

The expanding evidence base has reinforced temozolomide's (TMZ) role as a cornerstone in glioblastoma multiforme (GBM) treatment. Several recent real-world studies and meta-analyses have shown that continuing TMZ therapy beyond the standard six cycles may provide additional survival benefits, particularly in patients with favorable molecular features such as MGMT promoter methylation or low Ki-67 expression. A meta-analysis published in Neuro-Oncology Advances in July 2023 reviewed outcomes from 2,578 patients across 16 nonrandomized studies and 5 randomized controlled trials. The analysis found that extended therapy was linked to a 28% reduction in disease progression and a 29% decrease in mortality risk, though most of these benefits were observed in retrospective cohorts. These findings highlight the need for further randomized investigations to establish the definitive value of prolonged adjuvant use. In addition, ongoing trials are evaluating TMZ in combination with immunotherapies and tumor-treating fields, supported by its tolerability and consistent clinical performance.

Cost-effectiveness and broad availability have also contributed to the widespread uptake of TMZ worldwide. The introduction of generic formulations has reduced treatment expenses, improving access without compromising therapeutic outcomes. Its favorable safety profile and established efficacy make it a preferred choice across diverse healthcare systems. A Phase IIa trial, published in March 2023 in the Journal of Clinical Oncology, assessed the SurVaxM vaccine alongside adjuvant TMZ in newly diagnosed GBM patients. Results demonstrated a median progression-free survival of 11.4 months and an overall survival of 25.9 months, with robust immune responses and no severe vaccine-related side effects, underscoring the potential of combination approaches. As emerging therapies evolve, many continue to build on TMZ as a foundation, reinforcing its critical role in the standard management of GBM.

The global uptake of tumor treating fields (TTF) continues to accelerate, supported by broader access and favorable reimbursement policies. Many healthcare systems have included TTF among reimbursable treatment options, reducing financial hurdles for patients who qualify. By late 2024, Novocure reported more than 4,000 patients worldwide actively using its Optune Gio TTF system, with strong adoption in regions such as the United States, Germany, France, and Japan. This rising user base reflects growing physician confidence and patient acceptance of the therapy across both advanced and emerging healthcare settings. The positive outcomes are also driving innovation, with ongoing efforts focused on technological upgrades and expanding its use in other tumor types. Collectively, these developments are positioning TTF as an integral element in the evolving management of glioblastoma multiforme.

The five-year survival data shows a marked difference between treatment approaches, with radiation therapy (RT) alone resulting in a 16.2% survival rate compared to 83.8% when combined with temozolomide (TMZ). This demonstrates the significant clinical advantage of multimodal therapy, particularly TMZ's role in enhancing outcomes for GBM patients. Such findings validate the continued reliance on TMZ as the backbone of GBM therapy and reinforce the demand for chemotherapy drugs in combination protocols. The evidence also supports healthcare providers' preference for integrated treatment approaches, strengthening the adoption of combination therapies in clinical practice.

From a market perspective, this survival benefit will continue to drive investment in combination regimens and fuel demand for supportive therapeutics like TMZ. Pharmaceutical companies are expected to leverage these outcomes by developing next-generation therapies that complement or enhance TMZ's effects, including immunotherapies and targeted agents. The higher survival outcomes with RT+TMZ will influence treatment guidelines, leading to broader reimbursement coverage and increased uptake across hospitals and cancer centers. This shift will not only sustain the dominance of TMZ in the GBM treatment market but also create opportunities for novel adjunctive therapies positioned alongside it.

Global Glioblastoma Multiforme Treatment Market Report Segmentation

This report forecasts revenue growth at global, regional, and country levels and provides an analysis of the latest industry trends in each of the sub-segments from 2021 to 2033. For this study, Grand View Research has segmented the global glioblastoma multiforme treatment market report based on treatment, end use, and region:

  • Treatment Outlook (Revenue, USD Million, 2021 - 2033)
  • Surgery
  • Radiation Therapy
  • Chemotherapy
    • Temozolomide
    • Lomustine
    • Carmustine Wafers
    • Other
  • Targeted Therapy (Bevacizumab)
  • Tumor Treating Field (TTF) Therapy
  • End Use Outlook (Revenue, USD Million, 2021 - 2033)
  • Hospitals
  • Clinics / Outpatient Centers
  • Ambulatory Surgical Centers
  • Others
  • Regional Outlook (Revenue, USD Million, 2021 - 2033)
  • North America
    • U.S.
    • Canada
    • Mexico
  • Europe
    • UK
    • Germany
    • France
    • Italy
    • Spain
    • Denmark
    • Sweden
    • Norway
  • Asia Pacific
    • Japan
    • China
    • India
    • Australia
    • South Korea
    • Thailand
  • Latin America
    • Brazil
    • Argentina
  • Middle East & Africa
    • South Africa
    • Saudi Arabia
    • UAE
    • Kuwait

Table of Contents

Chapter 1. Methodology and Scope

  • 1.1. Market Segmentation & Scope
  • 1.2. Segment Definitions
    • 1.2.1. Treatment
    • 1.2.2. End Use
  • 1.3. Estimates and Forecast Timeline
  • 1.4. Research Methodology
  • 1.5. Information Procurement
    • 1.5.1. Purchased Database
    • 1.5.2. GVR's Internal Database
    • 1.5.3. Secondary Sources
    • 1.5.4. Primary Research
  • 1.6. Information Analysis
    • 1.6.1. Data Analysis Models
  • 1.7. Market Formulation & Data Visualization
  • 1.8. Model Details
    • 1.8.1. Commodity Flow Analysis
  • 1.9. List of Secondary Sources
  • 1.10. Objectives

Chapter 2. Executive Summary

  • 2.1. Market Snapshot
  • 2.2. Segment Snapshot
  • 2.3. Competitive Landscape Snapshot

Chapter 3. Glioblastoma Multiforme Treatment Market Variables, Trends, & Scope

  • 3.1. Market Lineage Outlook
  • 3.2. Market Dynamics
    • 3.2.1. Market Driver Analysis
    • 3.2.2. Market Restraint Analysis
  • 3.3. Business Environment Analysis
    • 3.3.1. Industry Analysis - Porter's Five Forces Analysis
      • 3.3.1.1. Supplier Power
      • 3.3.1.2. Buyer Power
      • 3.3.1.3. Substitution Threat
      • 3.3.1.4. Threat of New Entrants
      • 3.3.1.5. Competitive Rivalry
    • 3.3.2. PESTLE Analysis
    • 3.3.3. Pipeline Analysis
    • 3.3.4. Patent Expiry Analysis
    • 3.3.5. Pricing Analysis

Chapter 4. Glioblastoma Multiforme Treatment Market: Treatment Business Analysis

  • 4.1. Treatment Market Share, 2025 & 2033
  • 4.2. Treatment Segment Dashboard
  • 4.3. Market Size & Forecasts and Trend Analysis, by Treatment, 2021 to 2033 (USD Million)
  • 4.4. Surgery
    • 4.4.1. Surgery Market, 2021 - 2033 (USD Million)
  • 4.5. Radiation Therapy
    • 4.5.1. Radiation Therapy Market, 2021 - 2033 (USD Million)
  • 4.6. Chemotherapy
    • 4.6.1. Chemotherapy Market, 2021 - 2033 (USD Million)
    • 4.6.2. Temozolomide
      • 4.6.2.1. Temozolomide Market, 2021 - 2033 (USD Million)
    • 4.6.3. Lomustine
      • 4.6.3.1. Lomustine Market, 2021 - 2033 (USD Million)
    • 4.6.4. Carmustine Wafers
      • 4.6.4.1. Carmustine Wafers Market, 2021 - 2033 (USD Million)
    • 4.6.5. Other
      • 4.6.5.1. Other Market, 2021 - 2033 (USD Million)
  • 4.7. Targeted Therapy (Bevacizumab)
    • 4.7.1. Targeted Therapy (Bevacizumab) Market, 2021 - 2033 (USD Million)
  • 4.8. Tumor Treating Field (TTF) Therapy
    • 4.8.1. Tumor Treating Field (TTF) Therapy Market, 2021 - 2033 (USD Million)

Chapter 5. Glioblastoma Multiforme Treatment Market: End Use Business Analysis

  • 5.1. End Use Market Share, 2025 & 2033
  • 5.2. End Use Segment Dashboard
  • 5.3. Market Size & Forecasts and Trend Analysis, by End Use, 2021 to 2033 (USD Million)
  • 5.4. Hospitals
    • 5.4.1. Hospitals Market, 2021 - 2033 (USD Million)
  • 5.5. Clinics / Outpatient Centers
    • 5.5.1. Clinics / Outpatient Centers Market, 2021 - 2033 (USD Million)
  • 5.6. Ambulatory Surgical Centers
    • 5.6.1. Ambulatory Surgical Centers Market, 2021 - 2033 (USD Million)
  • 5.7. Others
    • 5.7.1. Others Market, 2021 - 2033 (USD Million)

Chapter 6. Glioblastoma Multiforme Treatment Market: Regional Estimates & Trend Analysis

  • 6.1. Regional Market Share Analysis, 2025 & 2033
  • 6.2. Regional Market Dashboard
  • 6.3. Market Size & Forecasts Trend Analysis, 2021 to 2033:
  • 6.4. North America
    • 6.4.1. North America Glioblastoma Multiforme Treatment Market Estimates and Forecasts, By Country, 2021 - 2033 (USD Million)
    • 6.4.2. U.S.
      • 6.4.2.1. Key Country Dynamics
      • 6.4.2.2. Target Disease Prevalence
      • 6.4.2.3. Regulatory Framework
      • 6.4.2.4. Reimbursement Framework
      • 6.4.2.5. U.S. Glioblastoma Multiforme Treatment Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 6.4.3. Canada
      • 6.4.3.1. Key Country Dynamics
      • 6.4.3.2. Target Disease Prevalence
      • 6.4.3.3. Regulatory Framework
      • 6.4.3.4. Reimbursement Framework
      • 6.4.3.5. U.S. Glioblastoma Multiforme Treatment Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 6.4.4. Mexico
      • 6.4.4.1. Key Country Dynamics
      • 6.4.4.2. Target Disease Prevalence
      • 6.4.4.3. Regulatory Framework
      • 6.4.4.4. Reimbursement Framework
      • 6.4.4.5. Mexico Glioblastoma Multiforme Treatment Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 6.5. Europe
    • 6.5.1. Europe Glioblastoma Multiforme Treatment Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 6.5.2. UK
      • 6.5.2.1. Key Country Dynamics
      • 6.5.2.2. Target Disease Prevalence
      • 6.5.2.3. Regulatory Framework
      • 6.5.2.4. Reimbursement Framework
      • 6.5.2.5. Uk Glioblastoma Multiforme Treatment Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 6.5.3. Germany
      • 6.5.3.1. Key Country Dynamics
      • 6.5.3.2. Target Disease Prevalence
      • 6.5.3.3. Regulatory Framework
      • 6.5.3.4. Reimbursement Framework
      • 6.5.3.5. Germany Glioblastoma Multiforme Treatment Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 6.5.4. France
      • 6.5.4.1. Key Country Dynamics
      • 6.5.4.2. Target Disease Prevalence
      • 6.5.4.3. Regulatory Framework
      • 6.5.4.4. Reimbursement Framework
      • 6.5.4.5. France Glioblastoma Multiforme Treatment Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 6.5.5. Italy
      • 6.5.5.1. Key Country Dynamics
      • 6.5.5.2. Target Disease Prevalence
      • 6.5.5.3. Regulatory Framework
      • 6.5.5.4. Reimbursement Framework
      • 6.5.5.5. Italy Glioblastoma Multiforme Treatment Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 6.5.6. Spain
      • 6.5.6.1. Key Country Dynamics
      • 6.5.6.2. Target Disease Prevalence
      • 6.5.6.3. Regulatory Framework
      • 6.5.6.4. Reimbursement Framework
      • 6.5.6.5. Spain Glioblastoma Multiforme Treatment Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 6.5.7. Denmark
      • 6.5.7.1. Key Country Dynamics
      • 6.5.7.2. Target Disease Prevalence
      • 6.5.7.3. Regulatory Framework
      • 6.5.7.4. Reimbursement Framework
      • 6.5.7.5. Denmark Glioblastoma Multiforme Treatment Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 6.5.8. Sweden
      • 6.5.8.1. Key Country Dynamics
      • 6.5.8.2. Target Disease Prevalence
      • 6.5.8.3. Regulatory Framework
      • 6.5.8.4. Reimbursement Framework
      • 6.5.8.5. Sweden Glioblastoma Multiforme Treatment Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 6.5.9. Norway
      • 6.5.9.1. Key Country Dynamics
      • 6.5.9.2. Target Disease Prevalence
      • 6.5.9.3. Regulatory Framework
      • 6.5.9.4. Reimbursement Framework
      • 6.5.9.5. Norway Glioblastoma Multiforme Treatment Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 6.6. Asia Pacific
    • 6.6.1. Asia Pacific Glioblastoma Multiforme Treatment Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 6.6.2. Japan
      • 6.6.2.1. Key Country Dynamics
      • 6.6.2.2. Target Disease Prevalence
      • 6.6.2.3. Regulatory Framework
      • 6.6.2.4. Reimbursement Framework
      • 6.6.2.5. Japan Glioblastoma Multiforme Treatment Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 6.6.3. China
      • 6.6.3.1. Key Country Dynamics
      • 6.6.3.2. Target Disease Prevalence
      • 6.6.3.3. Regulatory Framework
      • 6.6.3.4. Reimbursement Framework
      • 6.6.3.5. China Glioblastoma Multiforme Treatment Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 6.6.4. India
      • 6.6.4.1. Key Country Dynamics
      • 6.6.4.2. Target Disease Prevalence
      • 6.6.4.3. Regulatory Framework
      • 6.6.4.4. Reimbursement Framework
      • 6.6.4.5. India Glioblastoma Multiforme Treatment Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 6.6.5. Australia
      • 6.6.5.1. Key Country Dynamics
      • 6.6.5.2. Target Disease Prevalence
      • 6.6.5.3. Regulatory Framework
      • 6.6.5.4. Reimbursement Framework
      • 6.6.5.5. Australia Glioblastoma Multiforme Treatment Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 6.6.6. South Korea
      • 6.6.6.1. Key Country Dynamics
      • 6.6.6.2. Target Disease Prevalence
      • 6.6.6.3. Regulatory Framework
      • 6.6.6.4. Reimbursement Framework
      • 6.6.6.5. South Korea Glioblastoma Multiforme Treatment Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 6.6.7. Thailand
      • 6.6.7.1. Key Country Dynamics
      • 6.6.7.2. Target Disease Prevalence
      • 6.6.7.3. Regulatory Framework
      • 6.6.7.4. Reimbursement Framework
      • 6.6.7.5. Thailand Glioblastoma Multiforme Treatment Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 6.7. Latin America
    • 6.7.1. Latin America Glioblastoma Multiforme Treatment Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 6.7.2. Brazil
      • 6.7.2.1. Key Country Dynamics
      • 6.7.2.2. Target Disease Prevalence
      • 6.7.2.3. Regulatory Framework
      • 6.7.2.4. Reimbursement Framework
      • 6.7.2.5. Japan Glioblastoma Multiforme Treatment Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 6.7.3. Argentina
      • 6.7.3.1. Key Country Dynamics
      • 6.7.3.2. Target Disease Prevalence
      • 6.7.3.3. Regulatory Framework
      • 6.7.3.4. Reimbursement Framework
      • 6.7.3.5. China Glioblastoma Multiforme Treatment Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 6.8. Middle East and Africa
    • 6.8.1. Middle East and Africa Glioblastoma Multiforme Treatment Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 6.8.2. South Africa
      • 6.8.2.1. Key Country Dynamics
      • 6.8.2.2. Target Disease Prevalence
      • 6.8.2.3. Regulatory Framework
      • 6.8.2.4. Reimbursement Framework
      • 6.8.2.5. South Africa Glioblastoma Multiforme Treatment Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 6.8.3. Saudi Arabia
      • 6.8.3.1. Key Country Dynamics
      • 6.8.3.2. Target Disease Prevalence
      • 6.8.3.3. Regulatory Framework
      • 6.8.3.4. Reimbursement Framework
      • 6.8.3.5. Saudi Arabia Glioblastoma Multiforme Treatment Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 6.8.4. UAE
      • 6.8.4.1. Key Country Dynamics
      • 6.8.4.2. Target Disease Prevalence
      • 6.8.4.3. Regulatory Framework
      • 6.8.4.4. Reimbursement Framework
      • 6.8.4.5. UAE Glioblastoma Multiforme Treatment Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 6.8.5. Kuwait
      • 6.8.5.1. Key Country Dynamics
      • 6.8.5.2. Target Disease Prevalence
      • 6.8.5.3. Regulatory Framework
      • 6.8.5.4. Reimbursement Framework
      • 6.8.5.5. Kuwait Glioblastoma Multiforme Treatment Market Estimates and Forecasts, 2021 - 2033 (USD Million)

Chapter 7. Competitive Landscape

  • 7.1. Participant Overview
  • 7.2. Company Market Position Analysis
  • 7.3. Company Categorization
  • 7.4. Strategy Mapping
  • 7.5. Company Profiles/Listing
    • 7.5.1. Merck & Co., Inc.
      • 7.5.1.1. Overview
      • 7.5.1.2. Financial Performance
      • 7.5.1.3. Treatment Benchmarking
      • 7.5.1.4. Strategic Initiatives
    • 7.5.2. Amgen, Inc.
      • 7.5.2.1. Overview
      • 7.5.2.2. Financial Performance
      • 7.5.2.3. Treatment Benchmarking
      • 7.5.2.4. Strategic Initiatives
    • 7.5.3. F. Hoffmann-La Roche Ltd.
      • 7.5.3.1. Overview
      • 7.5.3.2. Financial Performance
      • 7.5.3.3. Treatment Benchmarking
      • 7.5.3.4. Strategic Initiatives
    • 7.5.4. Pfizer Inc.
      • 7.5.4.1. Overview
      • 7.5.4.2. Financial Performance
      • 7.5.4.3. Treatment Benchmarking
      • 7.5.4.4. Strategic Initiatives
    • 7.5.5. Teva Pharmaceutical Industries Ltd.
      • 7.5.5.1. Overview
      • 7.5.5.2. Financial Performance
      • 7.5.5.3. Treatment Benchmarking
      • 7.5.5.4. Strategic Initiatives
    • 7.5.6. Sun Pharmaceutical Industries Ltd.
      • 7.5.6.1. Overview
      • 7.5.6.2. Financial Performance
      • 7.5.6.3. Treatment Benchmarking
      • 7.5.6.4. Strategic Initiatives
    • 7.5.7. Arbor Pharmaceuticals, LLC
      • 7.5.7.1. Overview
      • 7.5.7.2. Financial Performance
      • 7.5.7.3. Treatment Benchmarking
      • 7.5.7.4. Strategic Initiatives
    • 7.5.8. Amneal Pharmaceuticals
      • 7.5.8.1. Overview
      • 7.5.8.2. Financial Performance
      • 7.5.8.3. Treatment Benchmarking
      • 7.5.8.4. Strategic Initiatives
    • 7.5.9. Karyopharm Therapeutics, Inc.
      • 7.5.9.1. Overview
      • 7.5.9.2. Financial Performance
      • 7.5.9.3. Treatment Benchmarking
      • 7.5.9.4. Strategic Initiatives
    • 7.5.10. Sumitomo Dainippon Pharma Oncology, Inc. (Boston Biomedical, Inc.)
      • 7.5.10.1. Overview
      • 7.5.10.2. Financial Performance
      • 7.5.10.3. Treatment Benchmarking
      • 7.5.10.4. Strategic Initiatives

List of Tables

  • Table 1 List of secondary sources
  • Table 2 List of abbreviations
  • Table 3 Global glioblastoma multiforme treatment market, by region, 2021 - 2033 (USD Million)
  • Table 4 Global glioblastoma multiforme treatment market, by treatment, 2021 - 2033 (USD Million)
  • Table 5 Global glioblastoma multiforme treatment market, by end use, 2021 - 2033 (USD Million)
  • Table 6 North America glioblastoma multiforme treatment market, by country, 2021 - 2033 (USD Million)
  • Table 7 North America glioblastoma multiforme treatment market, by treatment, 2021 - 2033 (USD Million)
  • Table 8 North America glioblastoma multiforme treatment market, by end use, 2021 - 2033 (USD Million)
  • Table 9 U.S. glioblastoma multiforme treatment market, by treatment, 2021 - 2033 (USD Million)
  • Table 10 U.S. glioblastoma multiforme treatment market, by end use, 2021 - 2033 (USD Million)
  • Table 11 Canada glioblastoma multiforme treatment market, by treatment, 2021 - 2033 (USD Million)
  • Table 12 Canada glioblastoma multiforme treatment market, by end use, 2021 - 2033 (USD Million)
  • Table 13 Mexico glioblastoma multiforme treatment market, by treatment, 2021 - 2033 (USD Million)
  • Table 14 Mexico glioblastoma multiforme treatment market, by end use, 2021 - 2033 (USD Million)
  • Table 15 Europe glioblastoma multiforme treatment market, by country, 2021 - 2033 (USD Million)
  • Table 16 Europe glioblastoma multiforme treatment market, by treatment, 2021 - 2033 (USD Million)
  • Table 17 Europe glioblastoma multiforme treatment market, by end use, 2021 - 2033 (USD Million)
  • Table 18 UK glioblastoma multiforme treatment market, by treatment, 2021 - 2033 (USD Million)
  • Table 19 UK glioblastoma multiforme treatment market, by end use, 2021 - 2033 (USD Million)
  • Table 20 Germany glioblastoma multiforme treatment market, by treatment, 2021 - 2033 (USD Million)
  • Table 21 Germany glioblastoma multiforme treatment market, by end use, 2021 - 2033 (USD Million)
  • Table 22 France glioblastoma multiforme treatment market, by treatment, 2021 - 2033 (USD Million)
  • Table 23 France glioblastoma multiforme treatment market, by end use, 2021 - 2033 (USD Million)
  • Table 24 Italy glioblastoma multiforme treatment market, by treatment, 2021 - 2033 (USD Million)
  • Table 25 Italy glioblastoma multiforme treatment market, by end use, 2021 - 2033 (USD Million)
  • Table 26 Spain glioblastoma multiforme treatment market, by treatment, 2021 - 2033 (USD Million)
  • Table 27 Spain glioblastoma multiforme treatment market, by end use, 2021 - 2033 (USD Million)
  • Table 28 Norway glioblastoma multiforme treatment market, by treatment, 2021 - 2033 (USD Million)
  • Table 29 Norway glioblastoma multiforme treatment market, by end use, 2021 - 2033 (USD Million)
  • Table 30 Denmark glioblastoma multiforme treatment market, by treatment, 2021 - 2033 (USD Million)
  • Table 31 Denmark glioblastoma multiforme treatment market, by end use, 2021 - 2033 (USD Million)
  • Table 32 Sweden glioblastoma multiforme treatment market, by treatment, 2021 - 2033 (USD Million)
  • Table 33 Sweden glioblastoma multiforme treatment market, by end use, 2021 - 2033 (USD Million)
  • Table 34 Asia Pacific glioblastoma multiforme treatment market, by country, 2021 - 2033 (USD Million)
  • Table 35 Asia Pacific glioblastoma multiforme treatment market, by treatment, 2021 - 2033 (USD Million)
  • Table 36 Asia Pacific glioblastoma multiforme treatment market, by end use, 2021 - 2033 (USD Million)
  • Table 37 Japan glioblastoma multiforme treatment market, by treatment, 2021 - 2033 (USD Million)
  • Table 38 Japan glioblastoma multiforme treatment market, by end use, 2021 - 2033 (USD Million)
  • Table 39 China glioblastoma multiforme treatment market, by treatment, 2021 - 2033 (USD Million)
  • Table 40 China glioblastoma multiforme treatment market, by end use, 2021 - 2033 (USD Million)
  • Table 41 India glioblastoma multiforme treatment market, by treatment, 2021 - 2033 (USD Million)
  • Table 42 India glioblastoma multiforme treatment market, by end use, 2021 - 2033 (USD Million)
  • Table 43 Australia glioblastoma multiforme treatment market, by treatment, 2021 - 2033 (USD Million)
  • Table 44 Australia glioblastoma multiforme treatment market, by end use, 2021 - 2033 (USD Million)
  • Table 45 South Korea glioblastoma multiforme treatment market, by treatment, 2021 - 2033 (USD Million)
  • Table 46 South Korea glioblastoma multiforme treatment market, by end use, 2021 - 2033 (USD Million)
  • Table 47 Thailand glioblastoma multiforme treatment market, by treatment, 2021 - 2033 (USD Million)
  • Table 48 Thailand glioblastoma multiforme treatment market, by end use, 2021 - 2033 (USD Million)
  • Table 49 Latin America glioblastoma multiforme treatment market, by country, 2021 - 2033 (USD Million)
  • Table 50 Latin America glioblastoma multiforme treatment market, by treatment, 2021 - 2033 (USD Million)
  • Table 51 Latin America glioblastoma multiforme treatment market, by end use, 2021 - 2033 (USD Million)
  • Table 52 Brazil glioblastoma multiforme treatment market, by treatment, 2021 - 2033 (USD Million)
  • Table 53 Brazil glioblastoma multiforme treatment market, by end use, 2021 - 2033 (USD Million)
  • Table 54 Argentina glioblastoma multiforme treatment market, by treatment, 2021 - 2033 (USD Million)
  • Table 55 Argentina glioblastoma multiforme treatment market, by end use, 2021 - 2033 (USD Million)
  • Table 56 Middle East & Africa Glioblastoma multiforme treatment market, by country, 2021 - 2033 (USD Million)
  • Table 57 Middle East & Africa glioblastoma multiforme treatment market, by treatment, 2021 - 2033 (USD Million)
  • Table 58 Middle East & Africa glioblastoma multiforme treatment market, by end use, 2021 - 2033 (USD Million)
  • Table 59 South Africa glioblastoma multiforme treatment market, by treatment, 2021 - 2033 (USD Million)
  • Table 60 South Africa glioblastoma multiforme treatment market, by end use, 2021 - 2033 (USD Million)
  • Table 61 Saudi Arabia glioblastoma multiforme treatment market, by treatment, 2021 - 2033 (USD Million)
  • Table 62 Saudi Arabia glioblastoma multiforme treatment market, by end use, 2021 - 2033 (USD Million)
  • Table 63 UAE glioblastoma multiforme treatment market, by treatment, 2021 - 2033 (USD Million)
  • Table 64 UAE glioblastoma multiforme treatment market, by end use, 2021 - 2033 (USD Million)
  • Table 65 Kuwait glioblastoma multiforme treatment market, by treatment, 2021 - 2033 (USD Million)
  • Table 66 Kuwait glioblastoma multiforme treatment market, by end use, 2021 - 2033 (USD Million)

List of Figures

  • Fig. 1 Glioblastoma multiforme treatment market segmentation
  • Fig. 2 Market research process
  • Fig. 3 Data triangulation techniques
  • Fig. 4 Primary research pattern
  • Fig. 5 Market research approaches
  • Fig. 6 Value-chain-based sizing & forecasting
  • Fig. 7 Market formulation & validation
  • Fig. 8 Market snapshot
  • Fig. 9 Competitive landscape
  • Fig. 10 Glioblastoma multiforme treatment market dynamics
  • Fig. 11 Glioblastoma multiforme treatment market: Porter's five forces analysis
  • Fig. 12 Glioblastoma multiforme treatment market: PESTLE analysis
  • Fig. 13 Treatment market, 2021 - 2033 (USD Million)
  • Fig. 14 Surgery market, 2021 - 2033 (USD Million)
  • Fig. 15 Radiation therapy market, 2021 - 2033 (USD Million)
  • Fig. 16 Chemotherapy market, 2021 - 2033 (USD Million)
  • Fig. 17 Temozolomide market, 2021 - 2033 (USD Million)
  • Fig. 18 Lomustine market, 2021 - 2033 (USD Million)
  • Fig. 19 Carmustine Wafers market, 2021 - 2033 (USD Million)
  • Fig. 20 Other market, 2021 - 2033 (USD Million)
  • Fig. 21 Targeted therapy (Bevacizumab) market, 2021 - 2033 (USD Million)
  • Fig. 22 Tumor treating field (TTF) Therapy market, 2021 - 2033 (USD Million)
  • Fig. 23 End use market, 2021 - 2033 (USD Million)
  • Fig. 24 Hospitals market, 2021 - 2033 (USD Million)
  • Fig. 25 Clinics / outpatient centers market, 2021 - 2033 (USD Million)
  • Fig. 26 Ambulatory surgical centers market, 2021 - 2033 (USD Million)
  • Fig. 27 Others market, 2021 - 2033 (USD Million)
  • Fig. 28 Glioblastoma multiforme treatment market revenue, by region
  • Fig. 29 Regional marketplace: Key takeaways
  • Fig. 30 North America glioblastoma multiforme treatment market, 2021 - 2033 (USD Million)
  • Fig. 31 U.S. country dynamics
  • Fig. 32 U.S. glioblastoma multiforme treatment market, 2021 - 2033 (USD Million)
  • Fig. 33 Canada country dynamics
  • Fig. 34 Canada glioblastoma multiforme treatment market, 2021 - 2033 (USD Million)
  • Fig. 35 Mexico country dynamics
  • Fig. 36 Mexico glioblastoma multiforme treatment market, 2021 - 2033 (USD Million)
  • Fig. 37 Europe glioblastoma multiforme treatment market, 2021 - 2033 (USD Million)
  • Fig. 38 UK country dynamics
  • Fig. 39 UK glioblastoma multiforme treatment market, 2021 - 2033 (USD Million)
  • Fig. 40 Germany country dynamics
  • Fig. 41 Germany glioblastoma multiforme treatment market, 2021 - 2033 (USD Million)
  • Fig. 42 France country dynamics
  • Fig. 43 France glioblastoma multiforme treatment market, 2021 - 2033 (USD Million)
  • Fig. 44 Italy country dynamics
  • Fig. 45 Italy glioblastoma multiforme treatment market, 2021 - 2033 (USD Million)
  • Fig. 46 Spain country dynamics
  • Fig. 47 Spain glioblastoma multiforme treatment market, 2021 - 2033 (USD Million)
  • Fig. 48 Norway country dynamics
  • Fig. 49 Norway glioblastoma multiforme treatment market, 2021 - 2033 (USD Million)
  • Fig. 50 Sweden country dynamics
  • Fig. 51 Sweden glioblastoma multiforme treatment market, 2021 - 2033 (USD Million)
  • Fig. 52 Denmark country dynamics
  • Fig. 53 Denmark glioblastoma multiforme treatment market, 2021 - 2033 (USD Million)
  • Fig. 54 Asia Pacific glioblastoma multiforme treatment market, 2021 - 2033 (USD Million)
  • Fig. 55 Japan country dynamics
  • Fig. 56 Japan glioblastoma multiforme treatment market, 2021 - 2033 (USD Million)
  • Fig. 57 China country dynamics
  • Fig. 58 China glioblastoma multiforme treatment market, 2021 - 2033 (USD Million)
  • Fig. 59 India country dynamics
  • Fig. 60 India glioblastoma multiforme treatment market, 2021 - 2033 (USD Million)
  • Fig. 61 Australia country dynamics
  • Fig. 62 Australia glioblastoma multiforme treatment market, 2021 - 2033 (USD Million)
  • Fig. 63 South Korea country dynamics
  • Fig. 64 South Korea glioblastoma multiforme treatment market, 2021 - 2033 (USD Million)
  • Fig. 65 Thailand country dynamics
  • Fig. 66 Thailand glioblastoma multiforme treatment market, 2021 - 2033 (USD Million)
  • Fig. 67 Latin America glioblastoma multiforme treatment market, 2021 - 2033 (USD Million)
  • Fig. 68 Brazil country dynamics
  • Fig. 69 Brazil glioblastoma multiforme treatment market, 2021 - 2033 (USD Million)
  • Fig. 70 Argentina country dynamics
  • Fig. 71 Argentina glioblastoma multiforme treatment market, 2021 - 2033 (USD Million)
  • Fig. 72 MEA glioblastoma multiforme treatment market, 2021 - 2033 (USD Million)
  • Fig. 73 South Africa country dynamics
  • Fig. 74 South Africa glioblastoma multiforme treatment market, 2021 - 2033 (USD Million)
  • Fig. 75 Saudi Arabia country dynamics
  • Fig. 76 Saudi Arabia glioblastoma multiforme treatment market, 2021 - 2033 (USD Million)
  • Fig. 77 UAE country dynamics
  • Fig. 78 UAE glioblastoma multiforme treatment market, 2021 - 2033 (USD Million)
  • Fig. 79 Kuwait country dynamics
  • Fig. 80 Kuwait glioblastoma multiforme treatment market, 2021 - 2033 (USD Million)
  • Fig. 81 Company categorization
  • Fig. 82 Company market position analysis
  • Fig. 83 Strategic framework